Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Osteoclasts are cells of hematopoietic origin with a unique property of dissolving bone; their inhibition is a principle for treatment of diseases of bone loss. Protocols for generation of human osteoclasts in vitro have been described, but they often result in cells of low activity, raising questions on cell phenotype and suitability of such assays for screening of bone resorption inhibitors. Here we describe an optimized protocol for the production of stable amounts of highly active human osteoclasts. Mononuclear cells were isolated from human peripheral blood by density centrifugation, seeded at 600,000 cells per 96-well and cultured for 17 days in alpha-MEM medium, supplemented with 10% of selected fetal calf serum, 1 microM dexamethasone and a mix of macrophage-colony stimulating factor (M-CSF, 25 ng/ml), receptor activator of NFkappaB ligand (RANKL, 50 ng/ml), and transforming growth factor-beta1 (TGF-beta1, 5 ng/ml). Thus, in addition to widely recognized osteoclast-generating factors M-CSF and RANKL, other medium supplements and lengthy culture times were necessary. This assay reliably detected inhibition of osteoclast formation (multinucleated cells positive for tartrate-resistant acid phosphatase) and activity (resorbed area and collagen fragments released from bone slices) in dose response curves with several classes of bone resorption inhibitors. Therefore, this assay can be applied for monitoring bone-resorbing activity of novel drugs and as an clinical test for determining the capacity of blood cells to generate bone-resorbing osteoclasts. Isolation of large quantities of active human osteoclast mRNA and protein is also made possible by this assay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
NICHOLSON, G. C., MALAKELLIS, M., COLLIER, F. M., CAMERON, P. U., HOLLOWAY, W. R., GOUGH, T. J., GREGORIO-KING, C., KIRKLAND, M. A., & MYERS, D. E. (2000) · Clinical Science · doi:10.1042/cs0990133 · Cited by 107
Cited by
Liang, C., Guo, B., Wu, H., Shao, N., Li, D., Liu, J., Dang, L., Wang, C., Li, H., Li, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3791 · Cited by 354
Grigoriadis, A. E., Kennedy, M., Bozec, A., Brunton, F., Stenbeck, G., Park, I.-H., Wagner, E. F., & Keller, G. M. (2010) · Blood · doi:10.1182/blood-2009-07-234690 · Cited by 151
Sondergaard, B. C., Wulf, H., Henriksen, K., Schaller, S., Oestergaard, S., Qvist, P., Tankó, L. B., Bagger, Y. Z., Christiansen, C., & Karsdal, M. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.01.014 · Cited by 88
Retinoid-induced bone thinning is caused by subperiosteal osteoclast activity in adult rodents
Kneissel, M., Studer, A., Cortesi, R., & Šuša, M. (2005) · Bone · doi:10.1016/j.bone.2004.11.006 · Cited by 75
Self-citationGoto, Y., Aoyama, M., Sekiya, T., Kakita, H., Waguri-Nagaya, Y., Miyazawa, K., Asai, K., & Goto, S. (2016) · Stem Cells · doi:10.1002/stem.2440 · Cited by 27
Metadata
- Authors
- Susa, M., Luong-Nguyen, N.-H., Cappellen, D., Zamurovic, N., & Gamse, R.
- Venue
- Journal of Translational Medicine
- Published
- 2004-03-16
- Volume
- 2
- Issue
- 1
- Pages
- 6-6
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W1573842875
- Cited by
- 114
- References
- 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. https://app.cochat.ai/papers/10.1186/1479-5876-2-6
- The paper
- Susa, M., Luong-Nguyen, N.-H., Cappellen, D., Zamurovic, N., & Gamse, R. (2004). Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-2-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.